{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:19:14Z","timestamp":1771928354069,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antiphospholipid Syndrome (APS) is a systemic autoimmune disorder characterized by persistent antiphospholipid antibodies, associated with thrombosis or adverse pregnancy outcomes. Although non-thrombotic manifestations are less common than thrombotic events, they play an increasingly important role in diagnosis and disease progression, particularly in pediatric APS, and may interact with each other. Early recognition and management of these symptoms are crucial for patient prognosis. We present a case of 13-year-old male child presenting as autoimmune hemolytic anemia (AIHA) and myocarditis, with positive antiphospholipid antibodies (aPL). The patient showed significant improvement after combination therapy with corticosteroids, prophylactic low molecular weight heparin and aspirin. In addition, we conducted a comprehensive literature review on APS in conjunction with hemolytic anemia and cardiac complications, and found that in 171 APS cases with hemolytic anemia, 35 of them had cardiac complications. There were 8 cases of myocardial infarction (8\/171,4.7%) and 3 cases of myocarditis (3\/171, 1.8%). Compared with AIHA, the incidence of cardiopathy was significantly higher in microvascular hemolytic anemia (MAHA) (p = 0.020). Among 13 cases that recorded the time window from hemolytic anemia to cardiac symptoms, 92.3% of them developed cardiac complications within one year after the onset of hemolytic anemia, typically within a median interval of 3 months (ranging from 5 days to 2 years). Notably, 28.6% of the 35 cases reviewed involved children under 18, with nearly half presenting hemolytic anemia as the initial symptom. This case underscores APS patients with hemolytic anemia, particularly MAHA, require early intervention and timely cardiac follow-up. Given the current lack of definitive classification and treatment criteria for pediatric APS, future guidelines should incorporate the significance of non-thrombotic manifestations and emphasize early management strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1724748","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:44:03Z","timestamp":1769755443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Don\u2019t neglect the non-thrombotic manifestations of antiphospholipid syndrome in children \u2013 autoimmune hemolytic anemia and myocarditis: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Wanlin","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masumeh Nozzari","family":"Varkani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongkun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6399.1088","article-title":"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant","volume":"287","author":"Hughes","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.disamonth.2003.10.001","article-title":"Antiphospholipid syndrome","volume":"49","author":"Gezer","year":"2003","journal-title":"Dis Mon"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.08.003","article-title":"Primary, Secondary, Catastrophic Antiphospholipid Syndrome: is there a difference","volume":"114","author":"Harris","year":"2004","journal-title":"Thromb Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2024.2390637","article-title":"Pediatric antiphospholipid syndrome: is it the same as an adult","volume":"37","author":"Bitsadze","year":"2024","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/moh.0000000000000523","article-title":"Antiphospholipid syndrome in pediatric patients","volume":"26","author":"Tarango","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11926-020-00935-2","article-title":"Management of non-criteria manifestations in antiphospholipid syndrome","volume":"22","author":"Xourgia","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306075977","article-title":"Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis","volume":"16","author":"Krause","year":"2007","journal-title":"Lupus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114120","article-title":"Antiphospholipid antibodies and autoimmune haemolytic anaemia: A systematic review and meta-analysis","volume":"21","author":"Ames","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/93.8.523","article-title":"Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome","volume":"93","author":"Tektonidou","year":"2000","journal-title":"Qjm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103037","article-title":"Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis","volume":"21","author":"Cheng","year":"2022","journal-title":"A systematic review. Autoimmun Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.166029","article-title":"Lupus myocarditis: A case-control study from China","volume":"128","author":"Zhang","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210960","article-title":"European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1370285","article-title":"Antiphospholipid syndrome onset with hemolytic anemia and accompanied cardiocerebral events: a case report","volume":"12","author":"Zheng","year":"2024","journal-title":"Front Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1209","article-title":"Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry","volume":"122","author":"Avcin","year":"2008","journal-title":"Pediatrics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12968-018-0484-5","article-title":"Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification","volume":"20","author":"Puntmann","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e12708","DOI":"10.1002\/rth2.12708","article-title":"Thrombotic microangiopathies: An illustrated review","volume":"6","author":"Abou-Ismail","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2022-0142","article-title":"How to approach haemolysis: Haemolytic anaemia for the general physician","volume":"22","author":"Palmer","year":"2022","journal-title":"Clin Med (Lond)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.123.318780","article-title":"Basic mechanisms of hemolysis-associated thrombo-inflammation and immune dysregulation","volume":"43","author":"Dimitrov","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-bioeng-081622-031203","article-title":"Engineering therapeutics to detoxify hemoglobin, heme, and iron","volume":"25","author":"Pires","year":"2023","journal-title":"Annu Rev BioMed Eng"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00115","article-title":"Heme on innate immunity and inflammation","volume":"5","author":"Dutra","year":"2014","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013672","article-title":"Hypercoagulability and thrombotic complications in hemolytic anemias","volume":"94","author":"Ataga","year":"2009","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10067-017-3549-1","article-title":"Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort","volume":"36","author":"Shi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00610-9","article-title":"Serum calprotectin as a potential predictor of microvascular manifestations in patients with antiphospholipid syndrome","volume":"10","author":"Zhao","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000544","article-title":"Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease","volume":"2024","author":"Salter","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2638-5","article-title":"Causes and risk factors of death in patients with thrombotic microangiopathies","volume":"38","author":"Peigne","year":"2012","journal-title":"Intensive Care Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13804","article-title":"Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand","volume":"48","author":"Fox","year":"2018","journal-title":"Intern Med J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac070","article-title":"Non-criteria manifestations in the presence of antiphospholipid antibodies in a paediatric cohort","volume":"61","author":"Mor\u00e1n-\u00c1lvarez","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061240","article-title":"Non-criteria manifestations of juvenile antiphospholipid syndrome","volume":"10","author":"Miyamae","year":"2021","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2020.06.013","article-title":"Diagnosis, evaluation, and treatment of myocarditis in children","volume":"67","author":"Putschoegl","year":"2020","journal-title":"Pediatr Clin North Am"},{"key":"B36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40272-021-00484-w","article-title":"Managing antiphospholipid syndrome in children and adolescents: current and future prospects","volume":"24","author":"Islab\u00e3o","year":"2022","journal-title":"Paediatr Drugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1724748\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:27:51Z","timestamp":1771925271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1724748\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1724748"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1724748","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1724748"}}